CRIS Current Research Information System

CASTAGNETTI, FAUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.983
AS - Asia 10.952
EU - Europa 7.637
Continente sconosciuto - Info sul continente non disponibili 647
SA - Sud America 644
AF - Africa 563
OC - Oceania 19
Totale 32.445
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.786
VN - Vietnam 2.913
SG - Singapore 2.910
CN - Cina 2.776
GB - Regno Unito 2.049
IT - Italia 1.186
DE - Germania 922
SE - Svezia 902
HK - Hong Kong 616
FR - Francia 509
IN - India 475
BR - Brasile 460
NL - Olanda 447
RU - Federazione Russa 411
KR - Corea 261
IE - Irlanda 255
UA - Ucraina 255
JP - Giappone 242
BD - Bangladesh 223
ZA - Sudafrica 173
EE - Estonia 136
FI - Finlandia 134
TG - Togo 124
CI - Costa d'Avorio 103
CA - Canada 102
JO - Giordania 88
CH - Svizzera 87
BG - Bulgaria 79
AR - Argentina 67
PH - Filippine 65
ID - Indonesia 62
NG - Nigeria 53
PL - Polonia 51
TH - Thailandia 48
AT - Austria 45
BE - Belgio 45
SC - Seychelles 40
IQ - Iraq 39
TW - Taiwan 39
TR - Turchia 37
EC - Ecuador 36
MX - Messico 32
IR - Iran 28
ES - Italia 27
GR - Grecia 23
CL - Cile 22
PK - Pakistan 22
AU - Australia 17
CO - Colombia 16
RO - Romania 15
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 14
VE - Venezuela 14
JM - Giamaica 13
PY - Paraguay 13
AE - Emirati Arabi Uniti 12
ET - Etiopia 12
LB - Libano 12
MY - Malesia 12
HN - Honduras 11
KE - Kenya 10
CR - Costa Rica 9
GT - Guatemala 9
IL - Israele 9
LT - Lituania 9
PE - Perù 8
CZ - Repubblica Ceca 7
NP - Nepal 7
EG - Egitto 6
TN - Tunisia 6
AL - Albania 5
DK - Danimarca 5
GE - Georgia 5
LY - Libia 5
PT - Portogallo 5
TT - Trinidad e Tobago 5
DZ - Algeria 4
MD - Moldavia 4
NI - Nicaragua 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
TZ - Tanzania 4
UY - Uruguay 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
LV - Lettonia 3
NO - Norvegia 3
RS - Serbia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
EU - Europa 2
GM - Gambi 2
GP - Guadalupe 2
HR - Croazia 2
KZ - Kazakistan 2
Totale 31.774
Salva come PNG Salva come JPEG
Città #
Singapore 2.075
Southend 1.849
Ashburn 1.250
Fairfield 1.100
Chandler 869
San Jose 803
Ho Chi Minh City 631
Woodbridge 580
Hong Kong 573
Hanoi 571
Wilmington 557
Houston 537
Hefei 530
Seattle 515
Dong Ket 464
Beijing 415
Cambridge 393
Princeton 391
Ann Arbor 326
Boardman 262
Santa Clara 259
Dublin 253
Seoul 233
Lauterbourg 212
Council Bluffs 208
Tokyo 204
Nanjing 181
Bologna 179
New York 174
Los Angeles 162
Westminster 158
Padova 141
Dallas 138
Lomé 124
Jacksonville 123
Berlin 116
Helsinki 115
Buffalo 105
Abidjan 102
Milan 97
Da Nang 88
Amman 84
Haiphong 84
Jinan 82
Sofia 79
Chicago 78
Saint Petersburg 78
Turin 77
Shenyang 75
Redondo Beach 74
Bern 73
San Diego 62
Changsha 60
Frankfurt am Main 60
Rome 60
São Paulo 60
Bengaluru 58
Nanchang 57
Shanghai 54
Falls Church 50
Abeokuta 49
Munich 49
Tianjin 49
Guangzhou 48
Hebei 48
Brussels 44
Medford 44
Phoenix 44
Jiaxing 41
Warsaw 41
Jakarta 38
Orem 37
Hangzhou 36
Zhengzhou 35
Biên Hòa 34
Florence 34
Bremen 33
Des Moines 32
Nuremberg 32
Mülheim 31
Norwalk 30
Redmond 30
Brooklyn 29
Can Tho 29
Falkenstein 29
Montreal 28
Hải Dương 27
London 27
The Dalles 25
Chengdu 24
Ningbo 24
Atlanta 23
Dearborn 23
Taizhou 22
Wuhan 22
Bangkok 21
Toronto 21
Yubileyny 21
Baghdad 20
Mountain View 20
Totale 20.662
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 391
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 388
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 317
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 306
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 284
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 279
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 278
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 271
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 248
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 238
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 236
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 231
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 231
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 230
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 230
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 223
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 222
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 219
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 216
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 211
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 210
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 207
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 203
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 203
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 202
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 194
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 193
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries 193
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 192
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 191
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 191
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 190
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants 188
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 188
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 188
A review of the European LeukemiaNet recommendations for the management of CML 187
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 186
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 185
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 185
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 179
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 178
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 177
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 177
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 176
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 175
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 174
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 173
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 173
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 172
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 171
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 171
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 171
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 170
Leucemia mieloide cronica: terapia molecolare 169
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 169
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 169
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 168
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 167
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 167
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 166
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 165
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 164
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 164
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 164
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 163
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 163
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 163
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 162
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 161
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 160
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 160
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 159
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 159
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 159
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 156
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 156
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 156
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 156
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 156
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 155
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 154
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 152
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 152
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 151
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 150
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 150
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 150
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 149
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 147
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 146
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 146
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 146
Totale 19.350
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.411
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.912 0 86 239 290 326 198 59 218 159 223 526 588
2022/20233.603 412 564 195 432 260 261 143 190 586 98 303 159
2023/20241.052 47 153 62 101 77 260 66 61 42 65 63 55
2024/20254.376 116 692 381 312 519 219 272 108 46 536 267 908
2025/202610.644 1.045 1.070 1.005 740 1.091 505 916 511 1.977 902 524 358
2026/2027762 292 470 0 0 0 0 0 0 0 0 0 0
Totale 32.445